GlassScriptPhysician profile
Cristin M Bruns
NPI 1053364224
$158,923.69
in general payments reported to CMS, 2019-2025
35 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $44K · 2021: $19K · 2022: $14K · 2023: $10K · 2024: $4,010 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $1,437 · Consulting Fee: $638 · Education: $96.81 · Travel and Lodging: $52.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,375.00 |
| Food and Beverage | $1,436.73 |
| Consulting Fee | $637.50 |
| Education | $96.81 |
| Travel and Lodging | $52.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48,395.95 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $34,775.28 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $23,739.57 | 2019-2022 | |
| Lilly USA, LLC | $21,674.95 | 2019-2023 | Jardiance |
| Abbott Laboratories | $21,230.27 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $6,472.96 | 2019-2020 | |
| Corcept Therapeutics | $907.38 | 2019-2020 | |
| Medtronic, INC. | $342.65 | 2022-2025 | Simplera Sensor, Minimed 780g |
| Tandem Diabetes Care, INC. | $251.72 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $225.79 | 2019-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $140.04 | 2021 | |
| Insulet Corporation | $81.36 | 2019-2023 | Omnipod |
| Antares Pharma, INC. | $73.17 | 2019-2022 | |
| Amarin Pharma, INC. | $73.08 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $67.23 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53.45 | 2019 | |
| Amgen INC. | $51.30 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $38.12 | 2025 | Recorlev |
| Radius Health, INC. | $33.54 | 2019-2025 | Tymlos |
| Cequr Corporation | $31.21 | 2023-2025 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $28.67 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $27.57 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $24.85 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.59 | 2019 | |
| Ascendis Pharma Endocrinology INC | $18.01 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $17.92 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $17.63 | 2019 | |
| Neurocrine Biosciences, INC. | $16.54 | 2025 | |
| Sandoz INC. | $15.91 | 2019 | |
| Ibsa Pharma INC. | $15.28 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.80 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.08 | 2019 | |
| Aytu Biopharma, INC. | $12.31 | 2019 | |
| Siemens Medical Solutions USA, INC. | $11.57 | 2021 | |
| Merck Sharp & Dohme LLC | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristin Bruns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.